4.8 Review

Transforming Nuclear Medicine with Nanoradiopharmaceuticals

期刊

ACS NANO
卷 16, 期 4, 页码 5036-5061

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.1c10550

关键词

nuclear medicine; nanomedicine; nanoradiopharmaceuticals; multimodality; theranostics; radiation therapy; ion-beam therapy; neutron capture therapy; laser ablation

资金

  1. office of vice president for research and economic development at the University at Buffalo
  2. Russian Science Foundation [19-72-30012]
  3. Ministry of Science and Higher Education of Russian Federation [075-15-20211347]
  4. Institute of Eminence, University of Delhi, India [IOE/FRP/PCMS/2020/27]
  5. National Institutes of Health [R01CA257241, CA155446, R01DE028105]

向作者/读者索取更多资源

This review comprehensively discusses the application of nuclear nanomedicine in cancer diagnosis and therapy. Targeted radiation therapy using nanoparticles can enhance treatment efficacy and minimize damage to healthy tissues. The review also explores the potential of combining nuclear nanomedicine with other therapies for enhanced combination treatments, as well as advancements in radionuclide fabrication and laser ablation technologies.
Nuclear medicine is expected to make major advances in cancer diagnosis and therapy; tumor-targeted radiopharmaceuticals preferentially eradicate tumors while causing minimal damage to healthy tissues. The current scope of nuclear medicine can be significantly expanded by integration with nanomedicine, which utilizes nanoparticles for cancer diagnosis and therapy by capitalizing on the increased surface area-to-volume ratio, the passive/active targeting ability and high loading capacity, the greater interaction cross section with biological tissues, the rich surface properties of nanomaterials, the facile decoration of nanomaterials with a plethora of functionalities, and the potential for multiplexing several functionalities within one construct. This review provides a comprehensive discussion of nuclear nanomedicine using tumor-targeted nanoparticles for cancer radiation therapy with either pre-embedded radionuclides or nonradioactive materials which can be extrinsically triggered using various external nuclear particle sources to produce in situ radioactivity. In addition, it describes the prospect of combining nuclear nanomedicine with other modalities to enable synergistically enhanced combination therapies. The review also discusses advances in the fabrication of radionuclides as well as describes laser ablation technologies for producing nanoradiopharmaceuticals, which combine the ease of production with exceptional purity and rapid biodegradability, along with additional imaging or therapeutic functionalities. From a practical standpoint, these attributes of nanoradiopharmaceuticals may provide distinct advantages in diagnostic/therapeutic sensitivity and specificity, imaging resolution, and scalability of turnkey platforms. Coupling image-guided targeted radiation therapy with the possibility of in situ activation of nanomaterials as well as combining with other therapeutic modalities using a multifunctional nanoplatform could herald an era of exciting technological and therapeutic advances to radically transform the landscape of nuclear medicine. The review concludes with a discussion of current challenges and presents the authors' views on future opportunities to stimulate further research in this rewarding field of high societal impact.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据